Payers say NCCN guideline concordance sets a baseline for cancer coverage, but cost and formulary variation may still limit access.
News|Articles|October 10, 2025
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
Author(s)Rose McNulty
Fact checked by: Maggie L. Shaw
Explore the implications of the Most Favored Nation Order on US drug pricing reform and its potential impact on patient access and innovation.
Advertisement
Advertisement
Drug pricing reform is a complex undertaking, and developments related to the recent Most Favored Nation (MFN) executive order give insight into how the initiative may fit into broader drug pricing reform in the US. This was the basis of discussion at a webinar hosted by MJH Life Sciences® titled “Most Favored Nation Order: Legal Battles, Market Shifts, and the Future of Drug Pricing Reform.”
Related to this article
Topical ruxolitinib prescribing in Medicare Part D surged through 2024, but its cost per day runs 16 times higher than generic tacrolimus.
All 50 states have applied for CMS's GENEROUS Model, a Medicaid drug pricing program expected to save $64.3 billion over the next decade.
As peptides go mainstream, the FDA's shifting rules and a fractured state patchwork leave patients navigating a largely unregulated gray market.
Prior authorization and compounded drugs remain top obesity care access barriers, says NYU Langone's Holly Lofton, MD.
Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.
Accelerated approvals, surrogate end points, and high drug costs are reshaping cancer center formulary decisions, explained panelists at PCOC.
Congress's Mental Health TALK SAFE Act could expand telepsychiatry access by establishing permanent telehealth prescribing and licensing rules.
Advertisement
Advertisement